Glut1 and glut3 expression, but not capillary density, is increased by cobalt chloride in rat cerebrum and retina.
Treatment of rats with cobalt chloride [Co(II)], an agent that stimulates the expression of a set of hypoxia-responsive genes, for 10-12 days resulted in 1.45- and 1.40-fold increases in the content of Glut1 mRNA and Glut1 in cerebral gray matter, respectively (P<0. 05 for both changes). The increase in Glut1 content was associated with a significant increase in the content of Glut1 staining in microvessels isolated from cerebral gray matter, and in the intensity of Glut1 in microvessels of the frontal lobe and hippocampus assessed by immunohistochemistry. The abundance of Glut3 in cerebrum of Co(II)-treated rats also increased by 1.3-fold (P<0. 05), but the increase was not associated with a change in the content of Glut3 mRNA. In retina, treatment with Co(II) resulted in 2.48- and 1.23-fold increases in the content of Glut1 mRNA and Glut1 protein, respectively (P<0.05 for both changes); similar increases in Glut1 protein expression were observed in isolated retinal microvasculature. The content of Glut3 in retina also increased 1. 5-fold in Co(II)-treated rats (P<0.05). In addition, treatment with Co(II) resulted in a significant 2.2-fold increase in the expression of VEGF in the cerebrum. However, despite the Co(II)-induced increase in Glut1 expression in cerebral and retinal microvasculature and VEGF in cerebrum, there was no increase in the capillary density in either tissue. It is concluded that a 10-12 day exposure to Co(II), presumably acting through the hypoxia-signaling pathway, results in enhanced expression of both major glucose transporters in cerebral cortex and retina, without increasing the capillary density of either tissue.
Badr
G A
GA
Departments of Medicine and Physiology and Biophysics, and Diabetes Research Center, Case Western Reserve University, Cleveland, OH 44106-4951, USA.
Zhang
J Z
JZ
Tang
J
J
Kern
T S
TS
Ismail-Beigi
F
F
D000818:Animals; D016587:Antimutagenic Agents / Q000494:pharmacology*; D001812:Blood-Brain Barrier / Q000502:physiology; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology; D002196:Capillaries / Q000502:physiology; D002540:Cerebral Cortex / Q000098:blood supply / Q000737:chemistry*; D003035:Cobalt / Q000494:pharmacology*; D016228:Endothelial Growth Factors / Q000235:genetics; D015870:Gene Expression / Q000187:drug effects; D051272:Glucose Transporter Type 1; D051274:Glucose Transporter Type 3; D000860:Hypoxia / Q000503:physiopathology; D008222:Lymphokines / Q000235:genetics; D008297:Male; D008833:Microcirculation / Q000502:physiology; D009004:Monosaccharide Transport Proteins / Q000235:genetics*; D009419:Nerve Tissue Proteins; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D012160:Retina / Q000737:chemistry*; D012171:Retinal Vessels / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016587:Antimutagenic Agents; D016228:Endothelial Growth Factors; D051272:Glucose Transporter Type 1; D051274:Glucose Transporter Type 3; D008222:Lymphokines; D009004:Monosaccharide Transport Proteins; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; C495679:Slc2a1 protein, rat; C495690:Slc2a3 protein, rat; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D003035:Cobalt; C018021:cobaltous chloride